In a recent meta-analysis of 11 randomized controlled trials (RCTs) with over 4,500 patients, spironolactone treatment reduced HF hospitalization and BNP levels, and improved functional class in patients with HFmrEF or HFpEF (65). The gene discussed is NPPB; the disease is hydrops fetalis.